Alprostadil
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | PROSTIN VR PEDIATRIC | — | 1987-07-10 | fda.gov ↗ |
| Approved | US (FDA) | PROSTIN VR PEDIATRIC | — | 1981-10-16 | fda.gov ↗ |
Trials 29
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-11-06 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - THE GROUP'S "HA121-28" AND "ALPROSTADIL LIPOSOME INJECTION" WERE GRANTED CLINICAL TRIAL APPROVALS irasia.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-11-06 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - THE GROUP'S "HA121-28" AND "ALPROSTADIL LIPOSOME INJECTION" WERE GRANTED CLINICAL TRIAL APPROVALS irasia.com ↗ |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 40 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alprostadil | “Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission.” NCT02331745 ↗33“Drug (alprostadil/placebo - normal saline) to be nebulized; 5 micrograms via standard nebulizer within 4 hours, once.” NCT00314548 ↗ “including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA)” NCT02651350 ↗ “Safety and Efficacy of Alprostadil (FemLife Gel) in the Treatment of Female Sexual Arousal Disorder” NCT00572377 ↗ “ST-04 consists of an alprostadil polymer suspension designed for intraurethral application” NCT07601646 ↗ “Alprostadil, a prostaglandin E1 analog that has a vasodilator mechanism” NCT04536363 ↗ “20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine” NCT02584686 ↗ |
| Known as | caverject | “1 ml of caverject (alprostadil) 20 mcg” NCT06768177 ↗ |
| Known as | Eglandin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02350218 ↗ |
| Known as | FemLife Gel | “Safety and Efficacy of Alprostadil (FemLife Gel) in the Treatment of Female Sexual Arousal Disorder” NCT00572377 ↗ |
| Known as | lipo-PGE1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02628106 ↗ |
| Known as | Liprostin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00053716 ↗ |
| Known as | PGE1 | “Correction of the deficit in the perfusion pressure of the microcirculation that supplies the nerve by intravenous infusion of Prostaglandin E1 (PGE1) (Alprostadil), expected...” NCT03851562 ↗4“A number of clinical studies have proved that alprostadil (PGE1) has pharmacological effects of significant dilation of blood vessels, inhibition of plate aggregation,...” NCT03252626 ↗ “While the intravenous application PGE1, or alprostadil, can cause a decrease not only of the pulmonary but also of the systemic vascular tone” NCT00314548 ↗ “Prostaglandin E1 (alprostadil; PGE1)” PMID 35426776 ↗ Jul 2022 “Topical alprostadil (PGE-1)” NCT00324948 ↗ |
| Known as | Prostaglandin E1 | “Correction of the deficit in the perfusion pressure of the microcirculation that supplies the nerve by intravenous infusion of Prostaglandin E1 (PGE1) (Alprostadil), expected...” NCT03851562 ↗3“Alprostadil injection USP for intravascular infusion contains 500 micrograms Alprostadil, more commonly known as prostaglandin E1.” NCT03252626 ↗ “Prostaglandin E1 (alprostadil; PGE1)” PMID 35426776 ↗ Jul 2022 “Alprostadil (prostaglandin E1)” NCT00619229 ↗ |
| Known as | Prostaglandin E1 incorporated in lipid microspheres | “Prostaglandin E1 incorporated in lipid microspheres” NCT01245855 ↗ |
| Known as | Prostaglandin E2 | “Alprostadil (Prostaglandin E2) as adjuvant therapy” NCT04312555 ↗ |
| Known as | ST-04 | “This is a single arm dose escalation trial of a mucoadhesive intraurethral polymer suspension of alprostadil (ST-04) and will investigate the efficacy of 3 dose levels of ST-04...” NCT07601646 ↗ |
| Action | Inhibit | “Inhibition of platelets via PGE1 (Alprostadil)” NCT02895373 ↗ |
| Route | Intravenous | “a 12 hour intravenous infusion of Liprostin” NCT00053716 ↗ |